- Home
- CVBF vs EWTX Comparison
CVBF vs EWTX Comparison
Compare CVBF & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CVBF | EWTX |
|---|---|---|
| Founded | 1974 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.3B |
| IPO Year | 2009 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CVBF | EWTX |
|---|---|---|
| Price | $22.57 | $38.46 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 14 |
| Target Price | $26.08 | ★ $52.62 |
| AVG Volume (30 Days) | ★ 1.3M | 1.2M |
| Earning Date | 10-21-2026 | 11-09-2026 |
| Dividend Yield | ★ 3.52% | N/A |
| EPS Growth | ★ 5.56 | N/A |
| EPS | ★ 0.65 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $36.38 | N/A |
| Revenue Next Year | $14.66 | N/A |
| P/E Ratio | $34.93 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.01 | $16.70 |
| 52 Week High | $23.41 | $48.51 |
Technical Indicators
Market Signals| Indicator | CVBF | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 54.43 | 43.36 |
| Support Level | $22.22 | $37.33 |
| Resistance Level | $23.27 | $41.13 |
| Average True Range (ATR) | 0.43 | 1.83 |
| MACD | 0.09 | 0.18 |
| Stochastic Oscillator | 70.84 | 44.67 |
Price Performance
Historical ComparisonAbout CVBF CVB Financial Corporation
CVB Financial Corp is the holding company for Citizens Business Bank. Citizens Business Bank offers banking, lending, and investing services. It provides a full complement of lending products, including commercial, agribusiness, consumer, SBA, real estate, and construction loans, as well as equipment and vehicle leasing. Commercial products include lines of credit and other working capital financing, accounts receivable lending and letters of credit. It is a community bank with one reportable operating segment.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.